The psychopharmacology algorithm project at the Harvard south shore program: An update on psychotic depression

Harvard Review of Psychiatry

Volumn 16, Issue 4, 2008, Pages 235-247

  Hamoda, Hesham M ^b   Osser, David N ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Affective disorders; Psychopharmacology; Psychotic; Psychotic depression

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CLOZAPINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOTEPINE;

ADD ON THERAPY; ALGORITHM; DELUSION; DEPRESSIVE PSYCHOSIS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE TITRATION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HAMILTON SCALE; HUMAN; MONOTHERAPY; MOOD DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOLOGY ALGORITHM PROJECT AT THE HARVARD SOUTH SHORE PROGRAM; REVIEW; TARDIVE DYSKINESIA; TREATMENT PLANNING; TREATMENT RESPONSE;

ALGORITHMS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PSYCHOTIC DISORDERS;

EID: 48249106663     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1080/10673220802277904     Document Type: Review

References (100)

1. Adamson M. White paper: blueprint for collaboration. Symposium on diffusion, adoption, and maintenance of psychiatric treatment algorithms. Buffalo, NY: International Psychopharmacology Algorithm Project, 2006.
2. Adli M, Bauer M, Rush AJ. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 2006;59:1029-38.
3. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-51.
4. Osser D. Guidelines and algorithms for psychopharmacology: what is their role in 2007? Psychiatr Times 2007;21:55-9, 79.
5. Trivedi MH, Fava M, Marangell LB, Osser DN, Shelton RC. Use of treatment algorithms for depression. J Clin Psychiatry 2006;67:1458-65.
6. Osser DN. A systematic approach to the classification and pharmacotherapy of nonpsychotic major depression and dysthymia. J Clin Psychopharmacol 1993;13:133-44.
7. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: part one. Dir Psychiatry 1998;18:303-18.
8. Osser DN, Patterson RD. Algorithms for the pharmacotherapy of depression: part two. Dir Psychiatry 1998;18:319-36.
9. Dantzler A, Osser DN. Algorithms for the pharmacotherapy of acute depression in patients with bipolar disorder. Psychiatr Ann 1999;29:270-84.
10. Johnson J, Jowarth E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991;48:1075-81.
11. Ohayon M, Schatzberg A. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry 2002;159:1855-61.
12. Coryell W, Lavori P, Endicott J, Keller M, VanEerdewegh M. Outcome in schizoaffective, psychotic, and nonpsychotic depression. Course during a six- to 24-month follow-up. Arch Gen Psychiatry 1984;41:787-91.
13. Meyers BS, Greenberg R. Late-life delusional depression. J Affect Disord 1986;11:133-7.
14. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142:430-6.
15. Nelson J, Price L, Jatlow P. Neuroleptic dose and desipramine concentrations during combined treatment of unipolar delusional depression. Am J Psychiatry 1986;143:1151-4.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: APA, 1980.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., rev. Washington, DC: American Psychiatric Press, 1987.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA, 1994.
19. Rothschild A, Williamson D, Tohen M, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004;24:365-73.
20. Keller J, Schatzberg AF, Maj M. Current issues in the classification of psychotic major depression. Schizophr Bull 2007;33:877-85.
21. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992;149:733-45.
22. Bond TC, Rothschild AJ, Lerbinger J, Schatzberg AF. Delusional depression, family history, and DST response: a pilot study. Biol Psychiatry 1986;21:1239-46.
23. Nelson J, Davis J. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154:1497-503.
24. Anton R. Urinary free cortisol in psychotic depression. Biol Psychiatry 1987;22:24-34.
25. Arana G, Ross J, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry 1985;42:1193-204.
26. Brown RP, Stoll PM, Stokes PE, et al. Adrenocortical hyperactivity in depression: effects of agitation, delusions, melancholia, and other illness variables. Psychiatric Res 1988;23:167-78.
27. Thase M, Kupfer D, Ulrich R. Electroencephalographic sleep in psychotic depression: a valid subtype? Arch Gen Psychiatry 1986;43:886-93.
28. Contreras F, Menchon JM, Urretavizcaya M, Navarro MA, Vallejo J, Parker G. Hormonal differences between psychotic and non-psychotic melancholic depression. J Affect Disord 2007;100:65-73.
29. Keller J, Flores B, Gomez RG, et al. Cortisol circadian rhythm alterations in psychotic major depression. Biol Psychiatry 2006;60:275-81.
30. Hill S, Keshavan M, Thase M, Sweeney J. Neuropsychological dysfunction in antipsychotic-naïve first-episode unipolar psychotic depression. Am J Psychiatry 2004;161:996-1003.
31. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 2000;157:1095-100.
32. Rothschild A. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 2003;53:680-90.
33. Vythilingam M, Chen J, Bremner JD, Mazure CM, Maciejewski PK, Nelson JC. Psychotic depression and mortality. Am J Psychiatry 2003;160:574-6.
34. Rothschild AJ, Benes F, Hebben N, et al. Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry 1989;26:565-75.
35. Targum SD, Rosen LN, DeLisi LE, Weinberger DR, Citrin CM. Cerebral ventricular size in major depressive disorder: association with delusional symptoms. Biol Psychiatry 1983;18:329-36.
36. Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987;48:197-200.
37. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry 1981;138:328-33.
38. Nelson JC, Bowers MB Jr. Delusional unipolar depression: description and drug response. Arch Gen Psychiatry 1978;35:1321-8.
39. Andreescu C, Mulsant BH, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry 2007;68:194-200.
40. Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001;17:244-53.
41. Perry P, Morgan D, Smith R, Tsuang M. Treatment of unipolar depression accompanied by delusions. J Affect Disord 1982;4:195-200.
42. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996;19:237-52.
43. Pande A, Grunhaus l, Hasket R, Greden JF. Electroconvulsive therapy in delusional and nondelusional depressive disorder. J Affect Disord 1990;19:215-9.
44. Parker G, Hazdi-Pavlovic D, Hickie I, et al. Distinguishing psychotic and non-psychotic melancholia. J Affect Disord 1991;22:135-48.
45. Olfson M, Marcus S, Sackiem HA, Thompson J, Pincus HA. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998;155:22-9.
46. Birkenhäger TK, Renes JW, Pluijms EM. One-year follow-up after successful ECT: a naturalistic study in depressed inpatients. J Clin Psychiatry 2004;65:87-91.
47. Birkenhäger TK, Van den Broek WW, Mulder PG, De Lely A. One-year outcome of psychotic depression after successful electroconvulsive therapy. J ECT 2005;21:221-6.
48. Tsuchiyama K, Nagayama H, Yamada K, Isogawa K, Katsuragi S, Kiyota A. Predicting efficacy of electroconvulsive therapy in major depressive disorder. Psychiatry Clin Neurosci 2005;59:546-50.
49. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001;285:1299-307.
50. Meyers BS, Klimstra SA, Gabriele M, et al. Continuation treatment of delusional depression in older adults. Am J Geriatr Psychiatry 2001;9:415-22.
51. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med 2007;357:1939-45.
52. American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. 2nd ed. Washington, DC: American Psychiatric Press, 2001.
53. American Psychiatric Association. Practice guideline for the treatment of major depressive disorder (revision). Am J Psychiatry 2000;157(4 suppl):1-45.
54. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004.
55. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane database of systematic reviews 2005;4:CD004044.
56. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen WA. Pharmacological treatment for unipolar psychotic depression. Br J Psychiatry 2006;188:410-5.
57. Glassman AH, Roose SP. Delusional depression. Arch Gen Psychiatry 1981;38:424-7.
58. Chan CH, Janicak PG, Davis JM, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants. J Clin Psychiatry 1987;48:197-200.
59. Spiker DG, Perel JM, Hanin I, et al. The pharmacological treatment of delusional depression: part II. J Clin Psychopharmacol 1986;6:339-42.
60. Anton R, Burch E. Amoxapine vs amitriptyline combined with perphenazine in the treatment of psychotic depression. Am J Psychiatry 1990;147:1203-8.
61. Mulsant BH, Sweet RA, Rosen J, et al. A randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life. J Clin Psychiatry 2001;62:597-604.
62. Vattakatuchery JJ. Drug treatment for psychotic depression. Br J Psychiatry 2006;189:383.
63. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 1993;54:338-42.
64. Wolfersdorf M, Barg T, König F, Leibfarth M, Grünewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 1995;28:56-60.
65. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53.
66. Gossen D, De Suray J, Vandenhende F, Onkelinx C, Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002;4:E11.
67. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996;153:414-6.
68. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 1996;153:1631-3.
69. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double blinded controlled study. J Clin Psychiatry 2000;61:26-9.
70. Khan A, Warner HA, Brown WA. Symptoms reduction and suicide risk in patients treated with placebo in antidepressant clinical trails: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000;57:311-7.
71. Quitkin FM, McGrath PJ, Stewart JW, et al. Chronological milestones to guide drug change: when should clinicians switch antidepressants? Arch Gen Psychiatry 1996;53:785-92.
72. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial and growing. JAMA 2002;287:1840-7.
73. Nelson WH, Khan A, Orr WW Jr. Delusional depression. Phenomenology, neuroendocrine function, and tricyclic antidepressant response. J Affect Disord 1984;6:297-306.
74. Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J. Depression, delusions, and suicide. Am J Psychiatry 1983;140:1159-62.
75. McKenzie MS, McFarland BH. Trends in antidepressant overdoses. Pharmacoepidemiol Drug Saf 2007;16:513-23.
76. Woerner MG, Alvir PH, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1988;155:1521-8.
77. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-91.
78. Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:919-23.
79. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients. J Clin Psychopharmacol 2006;26:504-7.
80. Aronson T, Shukla S, Hoff A. Continuation therapy after ECT for delusional depression: a naturalistic study of prophylactic treatments and relapse. Convuls Ther 1987;3:251-9.
81. Kim W, Bahk W-M, Seo JS, et al. Depressive disorder with psychotic features. Annual meeting of the American Psychiatric Association. New Research NR 296. San Diego, CA, May 2007.
82. Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002;59:233-9.
83. Khan A, Cohen S, Stowell M, Capwell R, Avery D, Dunner DL. Treatment options in severe psychotic depression. Convuls Ther 1987;3:93-9.
84. Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986;143:1387-92.
85. Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983;140:318-22.
86. Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363-6.
87. Ranjan R, Meltzer H. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1995;40:253-8.
88. Jeyapaul P, Vieweg R. A case study evaluating the use of clozapine in depression with psychotic features. Ann Gen Psychiatry 2006;5:20.
89. Dassa D, Kaladjian A, Azorin JM, Giudicelli S. Clozapine in the treatment of psychotic refractory depression. Br J Psychiatry 1993;163:822-4.
90. Jeste D. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004;65 suppl 9:21-4.
91. Kane J. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004;65 suppl 9:16-20.
92. Khan A, Noonan C, Healey W. Is a single tricyclic antidepressant trial an active treatment for psychotic depression? Prog Neuropsychopharmacol Biol Psychiatry 1991;15:765-70.
93. Van den Broek WW, Birkenhäger TK, Mulder PG, Bruijn JA, Moleman P. A double blind study comparing imipramine with fluvoxamine in depressed inpatients. Psychopharmacology 2004;175:481-6.
94. Brujin JA, Moleman P, Mudler PG, et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed inpatients. Psychopharmacology 1996;127:231-7.
95. Rothschild A, Phillips K. Selective serotonin reuptake inhibitors and delusional depression. Am J Psychiatry 1999;156:977-8.
96. Zanardi R, Franchini L, Perez J, Gasperini M, Smeraldi E. Dr. Zanardi and colleagues reply. Am J Psychiatry 1999;156:978.
97. Avery D, Lubrano A. Depression treated with imipramine and ECT: the DeCarolis study reconsidered. Am J Psychiatry 1979;136:559-62.
98. Osser DN, Patterson RD, Levitt JJ. Guidelines, algorithms, and evidence-based psychopharmacology training for psychiatric residents. Acad Psychiatry 2005;29:180-6.
99. Meyers BS, Peasley-Miklus C, Flint AJ, Mulsant BH, Rothschild AJ. Methodological issues in designing a randomized controlled trial for psychotic depression: the STOP-PD study. Psychiatr Ann 2006;36:57-64.
100. Mulsant BH, Haskett RF, Prudic J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry 1997;154:559-61.